Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
May 06 2019 - 6:01PM
Business Wire
Omeros Corporation (NASDAQ: OMER), today announced that the
company will issue its first quarter 2019 financial results for the
period ended March 31, 2019, on Thursday, May 9, 2019, after the
market closes. Omeros management will host a conference call and
webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
to discuss the financial results as well as recent developments and
highlights.
Conference Call Details
To access the live conference call via phone, please dial (844)
831-4029 from the United States and Canada or (920) 663-6278
internationally. The participant passcode is 4095776. Please dial
in approximately 10 minutes prior to the start of the call. A
telephone replay will be available for one week following the call
and may be accessed by dialing (855) 859-2056 from the United
States and Canada or (404) 537-3406 internationally. The replay
passcode is 4095776.
To access the live and subsequently archived webcast of the
conference call, go to Omeros’ website at www.omeros.com and select
“Events” under the Investors section of the website. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company
committed to discovering, developing and commercializing
small-molecule and protein therapeutics for large-market as well as
orphan indications targeting inflammation, complement-mediated
diseases, disorders of the central nervous system and
immune-related diseases, including cancers. The company’s drug
product OMIDRIA® (phenylephrine and ketorolac intraocular solution)
1% / 0.3% is marketed for use during cataract surgery or
intraocular lens (IOL) replacement to maintain pupil size by
preventing intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. In the European Union,
the European Commission has approved OMIDRIA for use in
cataract surgery and other IOL replacement procedures to maintain
mydriasis (pupil dilation), prevent miosis (pupil constriction),
and to reduce postoperative eye pain. Omeros has multiple
Phase 3 and Phase 2 clinical-stage development programs focused on:
complement-associated thrombotic microangiopathies;
complement-mediated glomerulonephropathies; cognitive impairment;
and addictive and compulsive disorders. In
addition, Omeros has a diverse group of preclinical
programs and a proprietary G protein-coupled receptor (GPCR)
platform through which it controls 54 new GPCR drug targets and
corresponding compounds, a number of which are in preclinical
development. The company also exclusively possesses a novel
antibody-generating platform.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190506005816/en/
Jennifer Cook WilliamsCook Williams Communications, Inc.Investor
and Media Relations360.668.3701
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Jul 2024 to Aug 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Aug 2023 to Aug 2024